The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse Nexium capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis
- collapse Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with NSAIDs
- collapse Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients
- collapse Efficacy of esomeprazole 40mg q.d. versus placebo and 20mg q.d. versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDS including COX-2 selective NSAIDS.
- collapse Efficacy of esomeprazole 40mg q.d. versus placebo and esomeprazole 20mg q.d. versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs
- collapse Efficacy of esomeprazle 40mg Once Daily versus placebo and exomeprazole 20mg Once Daily versus placebo in treatment for relief of upper GI symptoms associated with continuous use of NSAIDS including COX-2 selective NSAIDS
- collapse A randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of esomeprazole once daily for the treatment of gastroesophageal reflux disease (GERD) in neonatal patients, including premature and up to 1 month corrected age
- collapse Quality of Life Validation in Laryngitis
- collapse A double-blind, randomised, parallel-group, multicentre, Phase III study to investigate the pharmacodynamic effect by assessment of the 24 hours intraesophageal pH level, the efficacy and safety of omeprazole 10mg and 20mg od in patients with non-erosive reflux disease (NERD)
- collapse A double-blind, randomised, parallel-group, multicentre, Phase III study to compare the efficacy of omeprazole 20mg and 10mg od for the four-week treatment of non-erosive reflux disease (NERD) with that of placebo od and to investigate safety
